Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,512 results
- VICTORY-AFIndependent statistical analysis of Evaluation of the Phased Radio Frequency Ablation System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01693120).
- Vidaza to Restore Hormone Thx Prostate: Complete Statistical AnalysisIndependent statistical analysis of Vidaza to Restore Hormone Thx Prostate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00384839).
- VillageWhereIndependent statistical analysis of Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02320903).
- Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing’s Sarcoma Family of Tumors: Complete Statistical AnalysisIndependent statistical analysis of Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- VINOIndependent statistical analysis of Vitamins in Nitrous Oxide Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00655980).
- Violence Prevention for Middle School Boys: Complete Statistical AnalysisIndependent statistical analysis of Violence Prevention for Middle School Boys: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03109184).
- VIOLETIndependent statistical analysis of A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- VIOLETIndependent statistical analysis of Vitamin D to Improve Outcomes by Leveraging Early Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03096314).
- VIPIndependent statistical analysis of Vanderbilt ICU Recovery Program Pilot Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03124342).
- VIPVIZAIndependent statistical analysis of Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849575).
- Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816: Complete Statistical AnalysisIndependent statistical analysis of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816: primary endpoint results, effect estimate…
- Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04268316).
- Virtual Reality in Labor and Delivery for Reduction in Pain: Complete Statistical AnalysisIndependent statistical analysis of Virtual Reality in Labor and Delivery for Reduction in Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03437031).
- Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms: Complete Statistical AnalysisIndependent statistical analysis of Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03113383).
- Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma: Complete Statistical AnalysisIndependent statistical analysis of Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00939484).
- VISTAIndependent statistical analysis of Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Vitamin D Deficiency and Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Deficiency and Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01337635).
- Vitamin D Levels in Children With IBD: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Levels in Children With IBD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00621257).
- Vitamin D Supplementation in Women With DCIS and/or LCIS: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D Supplementation in Women With DCIS and/or LCIS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02936999).
- Vitamin D to Prevent Autism in Newborn Siblings: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D to Prevent Autism in Newborn Siblings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366885).
- Vitamin D/Calcium Polyp Prevention Study: Complete Statistical AnalysisIndependent statistical analysis of Vitamin D/Calcium Polyp Prevention Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00153816).
- VitDColonIndependent statistical analysis of Vitamin D and Screening Colonoscopy or Polyp Surveillance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02269332).
- VIV-FIHIndependent statistical analysis of EasyCrossTM Device-Self-centering Catheter: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06412354).
- Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models: Complete Statistical AnalysisIndependent statistical analysis of Volatilome and Single-Lead Electrocardiogram Optimize Ischemic Heart Disease Diagnosis Using Machine Learning Models: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: Complete Statistical AnalysisIndependent statistical analysis of Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study: primary endpoint results, effect estimate with…
- VOLVERIndependent statistical analysis of Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00958074).
- Vorinostat in Treating Patients With Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00305773).
- Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00330161).
- Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00238303).
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM): Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with…
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma: primary endpoint results, effect…
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- VOTIVEIndependent statistical analysis of Virginia Opioid Overdose Treatment InitiatVE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03818399).
- VOYAGEIndependent statistical analysis of Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VOYAGERIndependent statistical analysis of A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- VPCIndependent statistical analysis of Co-Design and Pilot Testing of Peer-led Community Outreach to Improve Equity, Veteran-Centeredness and Uptake of Lung Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- VPESIndependent statistical analysis of Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- VRC 614Independent statistical analysis of Trial to Evaluate L9LS in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05019729).
- VRI01Independent statistical analysis of Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- VX-950-C211 – A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: Complete Statistical AnalysisIndependent statistical analysis of VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection: primary endpoint results,…
- Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): Complete Statistical AnalysisIndependent statistical analysis of Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02146378).
- Vyxeos for Induction of Low- or Intermediate-risk.: Complete Statistical AnalysisIndependent statistical analysis of Vyxeos for Induction of Low- or Intermediate-risk.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05599360).
- Wait and SeeIndependent statistical analysis of Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- WATCHMAN FLX™ CT Study: Complete Statistical AnalysisIndependent statistical analysis of WATCHMAN FLX™ CT Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05324371).